TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies

Conditions: Hematologic Malignancy; Non Hodgkin Lymphoma; Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia, Adult; Myelodysplastic Syndromes Interventions: Drug: TGRX-814 Sponsors: Shenzhen TargetRx, Inc.; Institute of Hematology& Blood Diseases Hospital, China Not yet recruiting

https://clinicaltrials.gov/study/NCT06206174

Source: ClinicalTrials.gov - January 15, 2024 Category: Research Source Type: clinical trials